Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:IPHANASDAQ:LENZNYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.98-3.4%$1.87$1.60▼$2.61$763.11M1.061.30 million shs1.11 million shsIPHAInnate Pharma$2.16-1.8%$2.04$1.29▼$3.51$199.10M0.27186,368 shs8,120 shsLENZLENZ Therapeutics$29.29-0.8%$25.72$14.42▼$38.93$824.40M0.41183,281 shs159,796 shsNUVBNuvation Bio$2.12-6.2%$2.04$1.54▼$3.97$721.36M1.422.35 million shs4.77 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%-2.46%+7.61%+0.51%-23.55%IPHAInnate Pharma0.00%+0.23%-4.42%+3.35%-21.17%LENZLENZ Therapeutics0.00%+3.98%-0.78%+35.98%+91.56%NUVBNuvation Bio0.00%-8.23%-13.82%+16.16%-31.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.905 of 5 stars0.05.00.00.04.20.01.3IPHAInnate Pharma3.2099 of 5 stars3.85.00.00.03.41.70.0LENZLENZ Therapeutics1.9174 of 5 stars3.60.00.00.03.52.50.0NUVBNuvation Bio3.5158 of 5 stars4.60.00.00.02.55.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AIPHAInnate Pharma 3.50Strong Buy$11.00409.26% UpsideLENZLENZ Therapeutics 3.17Buy$46.6059.10% UpsideNUVBNuvation Bio 3.17Buy$7.83269.50% UpsideCurrent Analyst Ratings BreakdownLatest IPHA, LENZ, NUVB, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.003/28/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.503/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$124.59M6.12N/AN/A$2.87 per share0.69IPHAInnate Pharma$12.62M15.78N/AN/A$0.69 per share3.13LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/ANUVBNuvation Bio$10.96M65.84N/AN/A$2.76 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.13N/A66.001.74-42.65%-2.56%-2.47%8/14/2025 (Estimated)IPHAInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/ALENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)NUVBNuvation Bio-$75.80M-$2.35N/AN/AN/AN/A-21.89%-17.86%8/4/2025 (Estimated)Latest IPHA, LENZ, NUVB, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05IPHAInnate Pharma0.922.92N/ALENZLENZ TherapeuticsN/A28.6328.63NUVBNuvation BioN/A9.579.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%IPHAInnate Pharma0.16%LENZLENZ Therapeutics54.32%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%IPHAInnate Pharma31.89%LENZLENZ Therapeutics38.40%NUVBNuvation Bio29.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.41 million356.14 millionOptionableIPHAInnate Pharma22092.18 million57.10 millionNot OptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/ANUVBNuvation Bio60340.26 million319.50 millionOptionableIPHA, LENZ, NUVB, and CRON HeadlinesRecent News About These CompaniesNuvation Bio (NYSE:NUVB) Stock Price Down 4.6% - What's Next?May 31 at 1:12 PM | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Millennium Management LLCMay 29, 2025 | marketbeat.comNuvation Bio stockholders approve board members and executive payMay 25, 2025 | uk.investing.comNuvation Bio’s SWOT analysis: taletrectinib approval could transform stock outlookMay 23, 2025 | uk.investing.comNorthern Trust Corp Acquires 563,627 Shares of Nuvation Bio Inc. (NYSE:NUVB)May 23, 2025 | marketbeat.comNuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual MeetingMay 21, 2025 | businesswire.comWexford Capital LP Purchases 294,452 Shares of Nuvation Bio Inc. (NYSE:NUVB)May 21, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Buy" from BrokeragesMay 20, 2025 | marketbeat.com4,164,178 Shares in Nuvation Bio Inc. (NYSE:NUVB) Bought by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Cuts Position in Nuvation Bio Inc. (NYSE:NUVB)May 16, 2025 | marketbeat.comNuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025May 13, 2025 | businesswire.comWedbush Issues Positive Outlook for Nuvation Bio EarningsMay 13, 2025 | marketbeat.comNuvation Bio to Participate in Upcoming Investor ConferencesMay 12, 2025 | gurufocus.comNuvation Bio Inc. (NUVB) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comNuvation Bio Inc. (NYSE:NUVB) Shares Bought by Algert Global LLCMay 11, 2025 | marketbeat.comNuvation Bio Inc. (NUVB): Among Billionaire David Abrams’ Stock Picks with Huge Upside PotentialMay 9, 2025 | insidermonkey.comNuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comNuvation Bio Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | businesswire.comNuvation Bio Inc. (NYSE:NUVB) Insider Sells $50,000.00 in StockMay 7, 2025 | insidertrades.comSusquehanna Fundamental Investments LLC Takes $572,000 Position in Nuvation Bio Inc. (NYSE:NUVB)May 6, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Shares Up 9.9% - Should You Buy?May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHA, LENZ, NUVB, and CRON Company DescriptionsCronos Group NASDAQ:CRON$1.98 -0.07 (-3.41%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.98 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Innate Pharma NASDAQ:IPHA$2.16 -0.04 (-1.82%) Closing price 05/30/2025 03:56 PM EasternExtended Trading$2.19 +0.03 (+1.39%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.LENZ Therapeutics NASDAQ:LENZ$29.29 -0.24 (-0.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$29.20 -0.09 (-0.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Nuvation Bio NYSE:NUVB$2.12 -0.14 (-6.19%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$2.12 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
